Swedish Orphan Biovitrum (SOBI.ST)

Executive Summary

Swedish Orphan Biovitrum (Sobi) is a leading rare disease company focused on innovative biologics. With a strong portfolio of approved hemophilia treatments and a pipeline targeting metabolic and hematologic disorders, Sobi is well-positioned for growth. The company recently hosted a Capital Markets Day (Feb 2026) and reported Q4/FY2025 results, highlighting revenue growth driven by its core products. Key pipeline assets include pacritinib (Phase 3 for myelofibrosis) and avatrombopag (Phase 2 for chemotherapy-induced thrombocytopenia), which address significant unmet needs. With a robust commercial base and advancing mid-to-late-stage trials, Sobi offers a balanced risk-reward profile in the rare disease space.

Upcoming Catalysts (preview)

• Q3 2026Avatrombopag Phase 2 Data for Chemotherapy-Induced Thrombocytopenia65% success
• H2 2027Pacritinib Phase 3 Update in Myelofibrosis50% success
• TBDPotential New Pipeline Entry or Licensing Deal40% success